Reporting on invasive lobular breast cancer in clinical trials: a systematic review.

Invasive lobular breast cancer (ILC) differs from invasive breast cancer of no special type in many ways. Evidence on treatment efficacy for ILC is, however, lacking. We studied the degree of documentation and representation of ILC in phase III/IV clinical trials for novel breast cancer treatments.

Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.

[This corrects the article DOI: 10.1017/cts.2023.

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?

Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clinical trials at our institution was significantly lower than that of patients with invasive ductal carcinoma (IDC). Possible links between requiring measurable disease and decreased enrollment of ILC patients require further study to ensure equitable trial access.

Early malnutrition screening and low cost protein supplementation in elderly patients admitted to a skilled nursing facility.

Background: Malnutrition among skilled nursing facility (SNF) patients can lead to hospital readmissions and multiple complications.

Purpose: To evaluate the effect of an existing malnutrition screening and management program on prealbumin levels of patients in skilled nursing facilities.

Methods: A retrospective design was used to evaluate baseline admission data including a prealbumin level.